IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
IN8bio, a clinical-stage biopharmaceutical company specializing in gamma-delta T cell therapies for cancer and autoimmune diseases, announced CEO William Ho will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The company will also hold one-on-one meetings with investors during the event, sharing upda…